Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis

References

• World Health Organization. 2016. World Health Organization treatment guidelines for drug-resistant tuberculosis. [cited 2018 Feb 2]. Avialable from: http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf
   Google Scholar
• World Health Organization. Tuberculosis. fact sheet. reviewed. [updated 2018 Jan; cited 2018 Feb 2]. Avialable from: http://www.who.int/mediacentre/factsheets/fs104/en/Assessed
   Google Scholar
• Vinnard C, King L, Munsiff S, et al. Long-term mortality of patients with tuberculous meningitis in New York City: a cohort study. Clin Infect Dis. 2017;15(64):401–407.
   Google Scholar
• Wang T, Feng G-D, Pang Y, et al. High rate of drug resistance among tuberculous meningitis cases in Shaanxi province, China. Sci Rep. 2016;6:25251.
   PubMed Web of Science ®Google Scholar
• Kaviyil JE, Ravikumar R. Diagnosis of tuberculous meningitis: current scenario from A tertiary neurocare centre In India. Indian J Tuberc. 2017;64:183–188.
   PubMedGoogle Scholar
• Caws M, Thwaites GE, Duy PM, et al. Molecular analysis of Mycobacterium tuberculosis causing multidrug-resistant tuberculosis meningitis. Int J Tuberc Lung Dis. 2007;11:202–208.
   PubMed Web of Science ®Google Scholar
• Vinnard C, Winston CA, Wileyto EP, et al. Isoniazid-resistant tuberculous meningitis, United States, 1993-2005. Emerg Infect Dis. 2011;17:539–542.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Chau TTH, Caws M, et al. Isoniazid resistance, mycobacterial genotype and outcome in Vietnamese adults with tuberculous meningitis. Int J Tuberc Lung Dis. 2002;6:865–871.
   PubMed Web of Science ®Google Scholar
• Gupta R, Kushwaha S, Thakur R, et al. Predictors of adverse outcome in patients of tuberculous meningitis in a multi-centric study from India. Indian J Tuberc. 2017;64:296–301.
   PubMedGoogle Scholar
• Kambli P, Nikam C, Shetty A, et al. Multi-drug resistant tuberculous meningitis. Indian J Med Microbiol. 2016;34:255.
   PubMed Web of Science ®Google Scholar
• Senbayrak S, Ozkutuk N, Erdem H, et al. Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study. Ann Clin Microbiol Antimicrob. 2015;14:47.
   PubMed Web of Science ®Google Scholar
• Sharma K, Modi M, Kaur H, et al. rpoB gene high-resolution melt curve analysis: a rapid approach for diagnosis and screening of drug resistance in tuberculous meningitis. Diagn Microbial Infect Dis. 2015;83:144–149.
   PubMed Web of Science ®Google Scholar
• Nhu NTQ, Heemskerk D, Thu DDA, et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. J Clin Microbiol. 2014;52:226–233.
   PubMed Web of Science ®Google Scholar
• Jain A, Dixit P, Jaiswal I, et al. Drug resistance in mycobacterial isolates from meningitis cases. Pediatr Infect Dis J. 2012;31:1317.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Visser DH, Bartens M, et al. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatr Infect Dis J. 2012;31:711–716.
   PubMed Web of Science ®Google Scholar
• Duo L, Ying B, Song X, et al. Molecular profile of drug resistance in tuberculous meningitis from southwest china. Clin Infect Dis. 2011;53:1067–1073.
   PubMed Web of Science ®Google Scholar
• Vinnard C, Winston CA, Wileyto EP, et al. Multidrug resistant tuberculous meningitis in the United States, 1993-2005. J Infect. 2011;63:240–242.
   PubMed Web of Science ®Google Scholar
• Yorsangsukkamol J, Chaiprasert A, Prammananan T, et al. Molecular analysis of Mycobacterium tuberculosis from tuberculous meningitis patients in Thailand. Tuberculosis. 2009;89:304–309.
   PubMed Web of Science ®Google Scholar
• Nagarathna S, Rafi W, Veenakumari HB, et al. Drug susceptibility profiling of tuberculous meningitis. Int J Tuberc Lung Dis. 2008;12:105–107.
   PubMed Web of Science ®Google Scholar
• Cecchini D, Ambrosioni J, Brezzo C, et al. Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome. AIDS. 2007;21:373–374.
   PubMed Web of Science ®Google Scholar
• Sharma D, Shah I, Patel S. Late onset hydrocephalus in children with tuberculous meningitis. J Fam Med Prim Care. 2016;5:873–874.
   PubMedGoogle Scholar
• Yoo KM, Joo E-J, Yeom J-S, et al. Dissemination of multidrug-resistant tuberculosis in a patient with acute HIV infection. BMC Infect Dis. 2014;14:462.
   PubMed Web of Science ®Google Scholar
• Sharma B, Handa R, Nagpal K, et al. Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis. Gen Hosp Psychiatry. 2014;36(451):e3–4.
   PubMedGoogle Scholar
• Bernard C, Brossier F, Fréchet-Jachym M, et al. Concomitant multidrug-resistant pulmonary tuberculosis and susceptible tuberculous meningitis. Emerg Infect Dis. 2014;20:506–507.
   PubMed Web of Science ®Google Scholar
• Mauro MV, Cavalcanti P, Ledonne R, et al. Description of primary multidrug-resistant tuberculous meningitis in an Italian child. Microb Drug Resist. 2012;18:71–73.
   PubMed Web of Science ®Google Scholar
• Ikegame S, Wakamatsu K, Fujita M, et al. A case of isoniazid-resistant miliary tuberculosis in which tuberculous meningitis paradoxically developed despite systemic improvement. J Infect Chemother. 2011;17:689–693.
   PubMed Web of Science ®Google Scholar
• Marschall J, Evison J-M, Droz S, et al. Disseminated tuberculosis following total knee arthroplasty in an HIV patient. Infection. 2008;36:274–278.
   PubMed Web of Science ®Google Scholar
• Kohli A, Kapoor R. Neurological picture embolic spread of tuberculomas in the brain in multidrug resistant tubercular meningitis. J Neurol Neurosurg Psychiatry. 2008;79:198.
   PubMed Web of Science ®Google Scholar
• Meybeck A, Calbet J, Ruimy R, et al. Multidrug-resistant tuberculous meningitis in an HIV-positive patient: a challenging disease. AIDS Patient Care STDs. 2007;21:149–153.
   PubMed Web of Science ®Google Scholar
• Ersoy Y, Ates O, Onal C, et al. Cerebellar abscess and syringomyelia due to isoniazid-resistant Mycobacterium tuberculosis. J Clin Neurosci. 2007;14:86–89.
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Barbò R, Rizzi M, et al. New times for an old disease: intracranial mass lesions caused by Mycobacterium tuberculosis in 5 HIV-negative African immigrants. Clin Infect Dis. 2004;39:e35–45.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Cleary T, Rodriguez A, et al. Multidrug-resistant tuberculous meningitis in patients with AIDS. Int J Tuberc Lung Dis. 2003;7:394–398.
   PubMed Web of Science ®Google Scholar
• Sofia M, Maniscalco M, Honoré N, et al. Familial outbreak of disseminated multidrug-resistant tuberculosis and meningitis. Int J Tuberc Lung Dis. 2001;5:551–558.
   PubMed Web of Science ®Google Scholar
• Silber E, Sonnenberg P, Saffer D, et al. Multidrug-resistant tuberculous meningitis in a health care worker. Int J Tuberc Lung Dis. 1998;2:774.
   PubMed Web of Science ®Google Scholar
• Horn DL, Hewlett D, Peterson S, et al. RISE-resistant tuberculous meningitis in AIDS patient. Lancet. 1993;341:177–178.
   PubMed Web of Science ®Google Scholar
• Rich AR, McCordock HA. The pathogenesis of tuberculous meningitis. Bull Johns Hopkins Hosp. 1933;52:5–37.
   Google Scholar
• Donald PR, Schaaf HS, Schoeman JF. Tuberculous meningitis and miliary tuberculosis: the Rich focus revisited. J Infect. 2005;50:193–195.
   PubMed Web of Science ®Google Scholar
• van Leeuwen LM, Boot M, Kuijl C, et al. Mycobacteria employ two different mechanisms to cross the blood-brain barrier. Cell Microbiol. 2018 May;10:e12858.
   Google Scholar
• Dastur DK, Manghani DK, Udani PM. Pathology and pathogenetic mechanisms in neurotuberculosis. Radiol Clin North Am. 1995;33:733–752.
   PubMed Web of Science ®Google Scholar
• Dastur DK, Lalitha VS, Udani PM, et al. The brain and meninges in tuberculous meningitis-gross pathology in 100 cases and pathogenesis. Neurol India. 1970;18:86–100.
   PubMedGoogle Scholar
• Zhang J, Hu X, Hu X, et al. Clinical features, outcomes and molecular profiles of drug resistance in tuberculous meningitis in non-HIV patients. Sci Rep. 2016;6:19072.
   PubMed Web of Science ®Google Scholar
• Crump JA, Reller LB. Two decades of disseminated tuberculosis at a university medical center: the expanding role of mycobacterial blood culture. Clin Infect Dis. 2003;37:1037–1043.
   PubMed Web of Science ®Google Scholar
• Solomons RS, Goussard P, Visser DH, et al. Chest radiograph findings in children with tuberculous meningitis. Int J Tuberc Lung Dis. 2015;19:200–204.
   PubMed Web of Science ®Google Scholar
• Miftode EG, Dorneanu OS, Leca DA, et al. Tuberculous meningitis in children and adults: a 10-year retrospective comparative analysis. PLoS One. 2015;10:e0133477.
   PubMed Web of Science ®Google Scholar
• Riste M, Hobden D, Pollard C, et al. Diagnosis of tuberculous meningitis with invasive pulmonary sampling. Lancet Infect Dis. 2018;18:25–26.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Chau TT, Stepniewska K, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet. 2002;360:1287–1292.
   PubMed Web of Science ®Google Scholar
• Sharma P, Garg RK, Verma R, et al. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: a retrospective evaluation. Eur J Intern Med. 2011;22:289–295.
   PubMed Web of Science ®Google Scholar
• Sinha MK, Garg RK, Anuradha H, et al. Vision impairment in tuberculous meningitis: predictors and prognosis. J Neurol Sci. 2010;290:27–32.
   PubMed Web of Science ®Google Scholar
• Tai MS, Viswanathan S, Rahmat K, et al. Cerebral infarction pattern in tuberculous meningitis. Sci Rep. 2016;6:38802.
   PubMed Web of Science ®Google Scholar
• Gupta R, Garg RK, Jain A, et al. Spinal cord and spinal nerve root involvement (myeloradiculopathy) in tuberculous meningitis. Medicine (Baltimore). 2015;94:e404.
   PubMed Web of Science ®Google Scholar
• Kumar K, Giribhattanavar P, Chandrashekar N, et al. Correlation of clinical, laboratory and drug susceptibility profiles in 176 patients with culture positive TBM in a tertiary neurocare centre. Diagn Microbiol Infect Dis. 2016;86:372–376.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Lan NTN, Dung NH, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis. 2005;192:79–88.
   PubMed Web of Science ®Google Scholar
• Padayatchi N, Bamber S, Dawood H, et al. Multidrug-resistant tuberculous meningitis in children in durban, South Africa. Pediatr Infect Dis J. 2006;25:147–150.
   PubMed Web of Science ®Google Scholar
• Patel VB, Padayatchi N, Bhigjee AI, et al. Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2004;38:851–856.
   PubMed Web of Science ®Google Scholar
• Kaplan SR, Topal J, Sosa L, et al. A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2018;10:9–16.
   Google Scholar
• Watt G, Selkon JB, Bautista S, et al. Drug resistant tuberculous meningitis in the Philippines: report of a case. Tubercle 1989;70:139–141.
   PubMedGoogle Scholar
• Rohlwink UK, Donald K, Gavine B, et al. Clinical characteristics and neurodevelopmental outcomes of children with tuberculous meningitis and hydrocephalus. Dev Med Child Neurol. 2016;58:461–468.
   PubMed Web of Science ®Google Scholar
• Güneş A, UlucÜ U, Aktar F, et al. Clinical, radiological and laboratory findings in 185 children with tuberculous meningitis at a single centre and relationship with the stage of the disease. Ital J Pediatr. 2015;41:75.
   PubMed Web of Science ®Google Scholar
• British Medical Research Council. Streptomycin treatment of tuberculous meningitis. BMJ. 1948;1:582–597.
   Google Scholar
• Abdelmalek R, Kanoun F, Kilani B, et al. Tuberculous meningitis in adults: MRI contribution to the diagnosis in 29 patients. Int J Infect Dis. 2006;10:372–377.
   PubMed Web of Science ®Google Scholar
• Garg RK, Malhotra HS, Jain A. Neuroimaging in tuberculous meningitis. Neurol India. 2016;64:219–227.
   PubMed Web of Science ®Google Scholar
• Singh AK, Malhotra HS, Garg RK, et al. Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis. BMC Infect Dis. 2016;16:306.
   PubMed Web of Science ®Google Scholar
• Marais S, Lai RPJ, Wilkinson KA, et al. Inflammasome activation underlying central nervous system deterioration in HIV-associated tuberculosis. J Infect Dis. 2017;21:677–686.
   Google Scholar
• Gonzales Zamora JA, Espinoza LA, Nwanyanwu RN. Neurosyphilis with concomitant cryptococcal and tuberculous meningitis in a patient with AIDS: report of a unique case. Case Rep Infect Dis. 2017;2017:4103858.
   PubMedGoogle Scholar
• Fang W, Zhang L, Liu J, et al. Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016. Emerg Microbes Infect. 2017;6:e73.
   PubMed Web of Science ®Google Scholar
• Sonneville R, Magalhaes E, Meyfroidt G. Central nervous system infections in immunocompromised patients. Curr Opin Crit Care. 2017;23:128–133.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lim KS. Three cases of neoplastic meningitis initially diagnosed with infectious meningitis in emergency department. Case Rep Emerg Med. 2013;2013:561475.
   PubMedGoogle Scholar
• Taylor G, Karlin N, Halfdanarson TR, et al. Leptomeningeal carcinomatosis in colorectal cancer: the mayo clinic experience. Clin Colorectal Cancer. 2018;17:e183–e187.
   PubMed Web of Science ®Google Scholar
• Ko MW, Turkeltaub PE, Lee EB, et al. Primary diffuse leptomeningeal gliomatosis mimicking a chronic inflammatory meningitis. J Neurol Sci. 2009;278:127–131.
   PubMed Web of Science ®Google Scholar
• Chaidir L, Annisa J, Dian S, et al. Microbiological diagnosis of adult tuberculous meningitis in a ten-year cohort in Indonesia. Diagn Microbiol Infect Dis. 2018;91:42–46.
   PubMed Web of Science ®Google Scholar
• Al-Mutairi NM, Ahmad S, Mokaddas E. Molecular screening versus phenotypic susceptibility testing of multidrug-resistant Mycobacterium tuberculosis isolates for streptomycin and ethambutol. Microb Drug Resist. 2018. Epub ahead of print. DOI:10.1089/mdr.2017.0294.
   PubMed Web of Science ®Google Scholar
• Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014;59:1364–1374.
   PubMed Web of Science ®Google Scholar
• Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5:a017863.
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A. 2002;9:3684–3689.
   Google Scholar
• Gupta R, Thakur R, Gupta P, et al. Evaluation of geno type mtbdrplus line probe assay for early detection of drug resistance in tuberculous meningitis patients in India. J Glob Infect Dis. 2015;7:5–10.
   PubMed Web of Science ®Google Scholar
• Bahr NC, Tugume L, Rajasingham R, et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert(®) MTB/RIF of centrifuged CSF. Int J Tuberc Lung. 2015;19:1209–1215.
   PubMed Web of Science ®Google Scholar
• Bahr NC, Marais S, Caws M, et al. GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last. Clin Infect Dis. 2016;62:1133–1135.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Next-generation Xpert® MTB/RIF Ultra assay recommended by WHO. [cited 2018 Feb 2]. Avialable from: http://www.who.int/tb/features_archive/Xpert-Ultra/en/assessed
   Google Scholar
• Bahr NC, Nuwagira E, Evans EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. 2018;18:68–75.
   PubMed Web of Science ®Google Scholar
• Chin JH. Xpert MTB/RIF Ultra: the long-awaited game changer for tuberculous meningitis? Eur Respir J. 2017;50(4): 1701201. pii.
   PubMed Web of Science ®Google Scholar
• Theron G, Peter J, Richardson M, et al. GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev. 2016;9:CD010705.
   PubMedGoogle Scholar
• Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med. 2017;377:1043–1054.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). [cited 2018 Feb 2]. Avialable from: http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1
   Google Scholar
• Akkerman OW, Odish OFF, Bolhuis MS, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis. 2016;62:523–524.
   PubMed Web of Science ®Google Scholar
• Van Toi P, Pouplin T, Tho NDK, et al. High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1061–1062:256–262.
   PubMed Web of Science ®Google Scholar
• Kalita J, Bhoi SK, Betai S, et al. Safety and efficacy of additional levofloxacin in tuberculous meningitis: a randomized controlled pilot study. Tuberculosis. 2016;98:1–6.
   PubMed Web of Science ®Google Scholar
• Alffenaar JWC, van Altena R, Bökkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis. 2009;49:1080–1082.
   PubMed Web of Science ®Google Scholar
• Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis. 2010;90:279–292.
   PubMed Web of Science ®Google Scholar
• Goff DC, Henderson DC, Evins AE, et al. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45:512–514.
   PubMed Web of Science ®Google Scholar
• Tsona A, Metallidis S, Foroglou N, et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother. 2010;22:17–19.
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet. 1989;16:74–85.
   PubMed Web of Science ®Google Scholar
• Phuapradit P, Supmonchai K, Kaojarern S, et al. The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis. J Neurol Neurosurg Psychiatry. 1990;53:81–82.
   PubMed Web of Science ®Google Scholar
• Ellard GA, Humphries MJ, Gabriel M, et al. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br Med J Clin Res Ed. 1987;294:284–285.
   PubMedGoogle Scholar
• Seifert M, Georghiou SB, Garfein RS, et al. Impact of fluoroquinolone use on mortality among a cohort of patients with suspected drug-resistant tuberculosis. Clin Infect Dis. 2017;65:772–778.
   PubMed Web of Science ®Google Scholar
• Te Brake L, Dian S, Ganiem AR, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents. 2015;(45):496–503.
   PubMedGoogle Scholar
• Heemskerk AD, Bang ND, Mai NTH, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016;374:124–134.
   PubMed Web of Science ®Google Scholar
• Mamatha HG, Shanthi V. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India. J Glob Antimicrob Resist. 2017;12:5–10.
   PubMed Web of Science ®Google Scholar
• Berning SE, Cherry TA, Iseman MD. Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. Clin Infect Dis. 2001;32:643–646.
   PubMed Web of Science ®Google Scholar
• Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs. 2010;24:655–667.
   PubMed Web of Science ®Google Scholar
• Alsleben N, Garcia-Prats AJ, Hesseling AC, et al. Successful treatment of a child with extensively drug-resistant tuberculous meningitis. J Pediatr Infect Dis Soc. 2015;4:e41–44.
   PubMed Web of Science ®Google Scholar
• van Toorn R, Schaaf HS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33:248–252.
   PubMed Web of Science ®Google Scholar
• Li H, Lu J, Liu J, et al. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J. 2016;35:607–610.
   PubMed Web of Science ®Google Scholar
• Sun F, Ruan Q, Wang J, et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother. 2014;58:6297–6301.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Kshetrimayum S, Gupta SK, et al. Linezolid-induced optic neuropathy in XDR pulmonary TB: a case series. Indian J Tuberc. 2017;64:129–133.
   PubMedGoogle Scholar
• Mehta S, Das M, Laxmeshwar C, et al. Linezolid-associated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India. PloS One. 2016;11:e0162138.
   PubMed Web of Science ®Google Scholar
• Shibata M, Shimokawa Y, Sasahara K, et al. Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis. Biopharm Drug Dispos. 2017;38:301–312.
   PubMed Web of Science ®Google Scholar
• Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology. 2015;85:1332–1341.
   PubMed Web of Science ®Google Scholar
• Donald PR. Chemotherapy for tuberculous meningitis. N Engl J Med. 2016;374:179–181.
   PubMed Web of Science ®Google Scholar
• Allana S, Shashkina E, Mathema B, et al. pnca gene mutations associated with pyrazinamide resistance in drug-resistant tuberculosis, South Africa and Georgia. Emerg Infect Dis. 2017;23:491–495.
   PubMed Web of Science ®Google Scholar
• Gegia M, Winters N, Benedetti A, et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:223–234.
   PubMed Web of Science ®Google Scholar
• Vinnard C, Winston CA, Wileyto EP, et al. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. BMJ. 2010;341:c4451.
   PubMed Web of Science ®Google Scholar
• Cresswell FV, Ssebambulidde K, Grint D, et al. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) [version 1; referees: 1 approved]. Wellcome Open Res. 2018;3:83.
   PubMedGoogle Scholar
• Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4:CD002244.
   PubMedGoogle Scholar
• Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741–1751.
   PubMed Web of Science ®Google Scholar
• Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007;196(Suppl 1):S86–107.
   PubMedGoogle Scholar
• Podlekareva DN, Efsen AM, Schultze A, et al. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV. 2016;3:e120–31.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Duc Bang N, Huy Dung N, et al.. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis. 2005;192:2134–2141.
   PubMed Web of Science ®Google Scholar
• Torok ME, Chau TTH, Mai PP, et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PloS One. 2008;3:e1772.
   PubMed Web of Science ®Google Scholar
• Fischl MA, Daikos GL, Uttamchandani RB, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med. 1992;117:184–190.
   PubMed Web of Science ®Google Scholar
• Tho DQ, Török ME, Yen NTB, et al. Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis. Antimicrob Agents Chemother. 2012;56:3074–3079.
   PubMed Web of Science ®Google Scholar
• Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016;316:191–210.
   PubMed Web of Science ®Google Scholar
• Török ME, Yen NTB, Chau TTH, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis. Clin Infect Dis. 2011;52:1374–1383.
   PubMed Web of Science ®Google Scholar
• Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen. Clin Infect Dis. 2017;65:20–28.
   PubMed Web of Science ®Google Scholar
• Harausz EP, Garcia-Prats AJ, Seddon JA, et al. New and repurposed drugs for pediatric multidrug-resistant tuberculosis Practice-Based Recommendations. Am J Respir Crit Care Med. 2017;195:1300–1310.
   PubMed Web of Science ®Google Scholar
• Maitra A, Bates S, Shaik M, et al. Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. Br Med Bull. 2016;118:138–148.
   PubMed Web of Science ®Google Scholar
• Ivanyi J, Zumla A. Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis. 2013;208:185–188.
   PubMed Web of Science ®Google Scholar
• Mai NT, Dobbs N, Phu NH, et al. A randomised double blind placebocontrolled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife. 2018;7:e33478, pii.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO end tb strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. [cited 2018 Feb 2]. Avialable from: http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf
   Google Scholar